Somatic Mutation Profile as a Predictor of Treatment Response and Survival in Unresectable Pancreatic Ductal Adenocarcinoma Treated with FOLFIRINOX and Gemcitabine Nab-Paclitaxel

(1) Background: Pancreatic ductal adenocarcinoma (PDAC) has low survival rates despite treatment advancements. Aim: This study aims to show how molecular profiling could possibly guide personalized treatment strategies, which may help improve survival outcomes in patients with PDAC. (2) Materials an...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2024-08, Vol.16 (15), p.2734
Main Authors: Paredes de la Fuente, Rodrigo, Sucre, Santiago, Ponce, Cristina, Rattani, Ahmed Anwer Ali, Peters, Mary Linton B
Format: Article
Language:English
Subjects:
1-Phosphatidylinositol 3-kinase
Adenocarcinoma
Cancer
Cancer patients
Cancer therapies
Cell cycle
Chemotherapy
Cytotoxicity
Decision making
Development and progression
Gemcitabine
Gene mutations
Genetic aspects
Mutation
Next-generation sequencing
Oncology
Oncology, Experimental
Paclitaxel
Pancreatic cancer
Patient outcomes
Patients
Precision medicine
Survival
Survival analysis
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:(1) Background: Pancreatic ductal adenocarcinoma (PDAC) has low survival rates despite treatment advancements. Aim: This study aims to show how molecular profiling could possibly guide personalized treatment strategies, which may help improve survival outcomes in patients with PDAC. (2) Materials and Methods: A retrospective analysis of 142 PDAC patients from a single academic center was conducted. Patients underwent chemotherapy and next-generation sequencing for molecular profiling. Key oncogenic pathways were identified using the Reactome pathway database. Survival analysis was performed using Kaplan-Meier curves and Cox Proportional Hazards Regression. (3) Results: Patients mainly received FOLFIRINOX (n = 62) or gemcitabine nab-paclitaxel (n = 62) as initial chemotherapy. The median OS was 13.6 months. Longer median OS was noted in patients with NOTCH (15 vs. 12.3 months, = 0.007) and KIT pathway mutations (21.3 vs. 12.12 months, = 0.04). Combinatorial pathway analysis indicated potential synergistic effects on survival. In the PFS, PI3K pathway (6.6 vs. 5.7 months, = 0.03) and KIT pathway (10.3 vs. 6.2 months, = 0.03) mutations correlated with improved PFS within the gemcitabine nab-paclitaxel subgroup. (4) Conclusions: Molecular profiling could play a role in PDAC for predicting outcomes and responses to therapies like FOLFIRINOX and gemcitabine nab-paclitaxel. Integrating genomic data into clinical decision-making can benefit PDAC treatment, though further validation is needed to fully utilize precision oncology in PDAC management.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16152734